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Summary 
Expression of class I major histocompatibility complex antigens on the surface of cells  trans- 
formed by adenovirus 12 (Ad12) is generally very low, and correlates with the in vivo oncoge- 
nicity of this virus. In primary embryonal fibroblasts (H-26) that express a transgenic swine class 
I antigen (PD 1), Ad12-mediated transformation results in inhibition in transport of newly syn- 
thesized class I molecules, as well as significant reduction in transporter associated with antigen 
presentation  (TAP)  gene expression.  In this report we show that reexpression of TAP mole- 
cules either by stable transfection of mouse TAP genes or by infection with recombinant vac- 
cinia viruses expressing human TAP genes, only partially reconstitutes the expression and trans- 
port  of the  class  I  molecueles.  Further  analysis  of Ad12-transformed  cells  revealed that  the 
expression of both LMP2 and LMP7, but not of other proteasome complex components, was 
downregulated,  resulting in altered proteolytic activities of the 20S proteasomes. Reconstitu- 
tion of both TAP and LMP expression resulted in complete restoration of PD1 cell surface ex- 
pression and enhanced expression of the endogenous H-2D  6 molecules. Despite high expres- 
sion of TAP,  LMP, and class I MHC molecules encoded by recombinant vaccinia viruses, in 
reconstituted Ad12-transformed cells, efficient transport of H-2 class I molecules could only be 
achieved by treatment of the cells with ~/-interferon. These data suggest that an additional fac- 
tor(s) that is interferon-regulated plays a role in the biosynthetic pathway of the class I complex, 
and that its function is deficient in this cell system. Thus, Ad12 viral transformation appears to 
suppress the expression of multiple genes that are important for antigen processing and presen- 
tation,  which  allows such  transformed cells  to  escape immune  surveillance.  This  coordinate 
downregnlation  of immune  response genes must likely occur through  their use of common 
regulatory elements. 
T 
he MHC class I genes play key roles in numerous im- 
munological  processes  involving  the  presentation  of 
"foreign"  antigens  for  recognition  by  CTL  (1).  By  this 
mechanism,  the  immune  system is  able  to  control  infec- 
tious  diseases  and  the  growth  of tumor cells.  Indeed,  tu- 
mors of various origin have been shown to express low lev- 
els of class I antigens, a characteristic that may contribute to 
their escape from immune surveillance (2-5).  Transfection 
of cell lines by class I MHC genes did not always result in 
the  expression  of class I  molecules on the  cell surface al- 
though  increased  levels  of class  I  mRNA  were  observed 
(6). Thus, the expression of class I MHC molecules may be 
suppressed during transcription of the genes or during synthe- 
sis, assembly, and transport of molecules to the cell surface. 
The biochemistry and cell biology of antigen processing 
and presentation by class I MHC molecules have been ana- 
lyzed in detail in the past six years (7,  8).  It is well estab- 
lished that the efficient transport of class I molecules to the 
cell surface depends on assembly of the heavy chain/i32m 
dimer with peptides. Such peptides, generated by cleavage 
of proteins in the cytosol, are actively transported by a het- 
erodirneric  complex known as transporter associated with 
antigen presentation  (TAP) l, into the  endoplasmic reticu- 
lure  (ER),  where  assembly  with  class  I  molecules  takes 
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the  Golgi apparatus to the  cell surface. Presumably, if the 
antigen-processing  machinery  of the  cell  is  functioning 
normally, the tumor-associated antigens and antigens origi- 
nating from oncogenic viruses generate such peptides for 
presentation to CTL (9-11). 
The function of the peptide transporters was determined 
by analysis  of class I assembly, transport,  and antigen pre- 
sentation in selected TAP-negative cell lines,  and in TAP 
knockout  mice.  Tumor  cell  lines  with  deletions  in  the 
MHC locus encompassing TAP and proteasome-associated 
LMP genes (such as T2 and LBL 721.174),  or with a TAP 
mutated  gene  (the  murine  RMA/S),  have  drastically  re- 
duced cell surface levels of class I molecules, and are defec- 
tive in class I transport and in antigen presentation (7, 8,  12, 
13).  Splenocytes from TAP1  knockout mice reveal similar 
characteristics (14).  Expression of class I molecules and an- 
tigen presentation can be restored by expressing TAP1  and 
TAP2 in these mutant cells  (15,  16),  indicating the indis- 
pensability of these molecules for class I expression and an- 
tigen presentation.  The proteases involved in  the  genera- 
tion  of peptide  antigens  have not  been clearly identified, 
although  attention  has focused on  the  multicatalytic  pro- 
teinase complex, or proteasome (17).  This protease consists 
of homologous subunits of 20-35 kD, and cleaves peptides 
and proteins after hydrophobic, basic, and acidic  residues. 
Several lines  of evidence  are  consistent  with  the  protea- 
some's role in antigen presentation.  These include  the  ef- 
fects of protease  inhibitors  on  the  generation  of peptides 
presented by class I molecules (18),  and the involvement of 
proteasome-mediated  ubiquitin-dependent  proteolysis  in 
antigen  presentation  (19).  The  two  proteasome  subunits, 
LMP2  and  LMP7,  are  encoded  by  genes  located  in  the 
MHC  and  are  closely linked  to  the  TAP  genes  (20-22). 
Transcription of LMP genes is induced by ",/-interferon and 
is followed by their incorporation into the proteasomes, re- 
organization  of the  proteasome subunits,  and  modulation 
of the proteolytic activities and cleavage site preferences of 
the  20S  proteasomes (23-27).  Thus,  LMP  molecules may 
play a  role in  controlling the production  of peptides  that 
are more compatible to class I binding.  Indeed, mice lack- 
ing the LMP7 component appear to have a partial defect in 
HY antigen presentation, and lower levels of certain class I 
alleles  (28).  In  addition,  LBL  721.174  cells  reconstituted 
with TAP1  and TAP2, but deleted of a sequence contain- 
ing the LMP  genes, still demonstrate selective deficiency in 
the presentation of certain antigens by HLA A2 and H-2D  b 
(29).  Moreover, the ability to present efficiently HLA A2- 
specific peptides could be restored by expressing the LMP7 
gene product  (29),  implying a role for LMP  molecules in 
supplying selective sets ofpeptides. 
Human tumors and tumor cell lines exhibiting defects in 
transport of class  I  molecules and in  antigen  presentation 
have been recently described  (30-34).  A  large number of 
Burkitt's lymphoma cell lines are unable to process intracel- 
lular antigenic determinants, and are highly resistant to class 
I-restricted CTL-mediated lysis (33,  35). Khanna et al. (33) 
demonstrated  that  both  peptide  transporters  (TAP1  and 
500 
TAP2)  are  downregulated  in  the  tumor cells,  resulting in 
inefficient transport  of peptides  to  the  ElK.  Downregula- 
tion  of class I  MHC  expression has been found also  in  a 
substantial  number of cervical carcinomas containing  hu- 
man papilloma virus 16 (34).  Cromme et al. (32, 34) dem- 
onstrated that in neoplastic cervical ceils that had lost their 
class  l  MHC  surface  expression,  the  peptide  transporter 
TAP1 was no longer expressed by some or all of the tumor 
cells  (36).  Some DNA viruses are associated with both hu- 
man and murine tumors that are deficient in class I molecule 
transport; cervical carcinomas harbor human papilloma vi- 
rus sequences  (34),  Burkitt's lymphomas contain EBV  se- 
quences  (35),  and  in  Ad12-transformed  rodent  cells  the 
early region oncogenes (E1A and E1B)  of Adl2 are essen- 
tial  and sufficient for Ad12-mediated  transformation  (37). 
We previously showed that reexpression of the TAP2 gene 
in an Ad12-transformed cell line,  which is downregulated 
for the expression of TAP genes, partially restored PD1  (a 
miniature  swine  class  I  transgene)  and  H-2D  u expression, 
but  did  not  reconstitute  that  of the  endogenous  H-2K  b 
(31).  These results raised the possibility that transformation 
by Ad12 and possibly other DNA viruses affects the expres- 
sion  of class I  molecules not  only by suppressing peptide 
transporter genes, but also  of other genes encoding mole- 
cules involved in the assembly and transport of class I mol- 
ecules. 
We  now  show  that  the  reexpression  of TAP  genes  in 
Ad12-transformed cells  is not sufficient for efficient trans- 
port  of class  I  molecules.  This  inhibition  is  coordinately 
regulated with deficiencies in specific sets  of peptides and 
the complete knockout of LMP genes in this system. Fur- 
thermore,  we suggest the  existence  of an additional  IFN- 
regulated  factor(s)  which  plays  a  role  in  the  biosynthetic 
pathway of the class I complex and its function is deficient 
in these cells. 
Materials and Methods 
Mice.  C57B1/10  mice, which are transgenic for a miniature 
swine class I antigen, PD1  (PD1 transgenic mice) have been pre- 
viously described (38). The mice, which are homozygous for the 
transgene, were bred at the Tel Aviv University breeding facility. 
Cell Cultures, Stable Transfections, and IFN Treatment.  The Ad12- 
transformed  (VAD12.79,  VAD12.42,  VAD12.20,  VAD12.25, 
VAD12.36), Ad5-transformed (ME1), EiAd5-transformed  (A501, 
A505),  one  of the  TAP-transfected  cell lines  (C1.1),  and  the 
normal  cell line  (M1) have been previously  described  (31, 38). 
Additional  TAP-transfected  cell lines are  described  in  the  text. 
PD 1.1 is a RadLV-induced thymic leukemia expressing high lev- 
els of class I antigens (39). 
Stable transfections were done by the calcium phosphate-DNA 
coprecipitation  method as previously described (31) with the fol- 
lowing modifications: the transfection cocktail contained  5 Ixg of 
pSG5 plasmids encoding LMP2, or LMP7 cDNAs, or both, and 1 
t-~g of the plasmid pBabe encoding the puromycin resistance gene 
(a kind gift from P. Murray, Whitehead  Institute, Boston,  MA). 
24 h after transfection the cells were washed with PBS and 24 h 
later the media were supplemented  with 2 ~g/ml of puromycin 
(Sigma Chemical Co., St. Louis, MO). 
Cell lines were treated  with ",/-IFN (100 U/ml)  (Boehringer 
Peptide Transporter and LMP Molecules in Adenovims-transformed Cells Mannheim, Mannheim, Germany) 48 h before harvesting or be- 
fore  infection with recombinant vaccinia viruses.  The cell lines 
were  maintained in DMEM  supplemented with  2  mM  gluta- 
mine, 10% FCS,  penicillin, streptomycin, gentamycin, and am- 
photericin B at the recommended concentrations (40). Media and 
supplements  were  purchased  from  Biological  Industries  (Bet 
Ha'emek, Israel). 
Recombinant Vaccinia Viruses and Infection.  Recombinant  vac- 
cinia viruses expressing H-2K  b and H-2D  a (41), human TAP1 and 
TAP2 (42), and the hybridoma TW2.3 which secretes antibodies 
directed against a vaccinia-encoded  protein (43) were kindly sup- 
plied by J.  Yewdell (National Institute of Allergy and Infectious 
Diseases, National Institutes of Health, Bethesda, MD). Infections 
with  recombinant vaccinia  viruses  and  immunoprecipitations 
were carried out as previously described  (30), with the following 
modifications:  cells were infected with 10 multiplicity of infec- 
tion/cefl for 60-90 rain, washed with PBS, and incubated in me- 
thionine-free medium for 15 min. Cells were then labeled for 30 
rain and immunoprecipitations  were carried out as described. An- 
tibodies directed against the vaccinia internal protein were used 
to monitor efficiency of infection. 
Probes and Plasmids.  Actin probe is a Pstl-PstI fragment from 
chicken 13 actin cDNA cloned in pBR322  (44); the TAP1 and 
TAP2 probes are XbaI-HindlII and KpnI-KpnI fragments  con- 
taining TAP1 and TAP2 cDNAs, respectively, cloned in pcDNAI 
Neo (Invitrogen, San Diego, CA); the LMP2 and LMP7 probes 
are EcoRI-EcoRI fragments containing cDNAs cloned in pGEM 
(Promega Corp.,  Madison, WI). The TAP- and LMP-containing 
plasmids were a kind gift from Dr. J. J.  Monaco (University of 
Cincinnati, Cincinnati, OH) (45). 
Antibodies.  The following antibodies were  used for FACS  | 
analyses and immunoprecipitations: 20.8.4S  (recognizes  Ixl/c~2 
epitope on H-2K  b)  (46); 28.14.8  (recognizes  an epitope on or3 
domain of H-2D  b heavy chains with or without associated 132m) 
(46-48); B22.249 and 27.11.13  (recognize  an or1  epitope and a 
public conformation-dependent  epitope, respectively, on H-2D  6) 
(46); 34.2.12  (recognizes  an epitope on the o~3 of H-2D  d)  (48); 
34.5.8  (recognizes  an epitope on the ~xl/cl2 domain of H-2D  a) 
(49). PT85A (recognizes a public determinant on swine lympho- 
cyte  antigens)  (50). Affinity-purified antibodies directed against 
LMP2, LMP7, and MC3 (51, 52) were used for Western analyses 
and  immunoprecipitations. FITC-conjugated goat  anti-mouse 
IgG was purchased  from Jackson ImmunoResearch Laboratories, 
Inc. (West Grove, PA). 
FACS  ~ Analysis.  Cells  were  harvested  by  mild  trypsiniza- 
tion, followed by washes in media supplemented with 5% FCS 
and 0.01% sodium azide. About 106 cells were incubated at 4~ 
with the  appropriate  concentration of the  first antibody for 30 
min, washed,  and then incubated in the dark for another 30 rain 
with the second antibody. Controls were stained with a first non- 
relevant antibody and a second antibody. Cells were washed with 
PBS  and fluorescence  intensity and analyzed  with a  cell sorter 
(Becton Dickinson & Co., Mountain View, CA). 
RNA Analysis.  Cytoplasmic RNA was prepared using a modifi- 
cation of the White and Bancroft method (53) as previously de- 
scribed (31). RNA was denatured and run on a 1.2% formaldehyde/ 
formamide  agarose  gel,  blotted  onto  a  Hybond-N membrane 
(Amersham International, Little  Chalfont, UK)  and hybridized 
with  the  appropriate  probe,  which  had  been  labeled  with 
[oL-32p]dCTP (Rotem Industries, Dimona, Israel), using a random 
priming labeling kit  (United States Biochemical Corp.,  Cleve- 
land, OH). 
The hybridization solution contained 4  ￿  SSC,  50% forma- 
mide,  0.2%  SDS,  0.1%  polyvinylpyrrolidone and  100  p,g/rnl 
sheared salmon sperm DNA. Hybridizations were carried  out at 
42~  followed by washes with 2 X SSC, 0.1% SDS at room tem- 
perature,  and 0.2 X SSC at temperatures ranging between 55 and 
65~  RX x-ray film (Fuji,  Tokyo, Japan)  was  exposed  to  the 
blot and the resulting bands were scanned with a densitometer. 
After stripping with a boiling solution of 0.1% SDS, the blot was 
used for additional hybridizations. 
Purification of20S Proteasomes.  Frozen  pellets  of  5  ￿  108 
A505  or VAD1279 cells were lysed and 20S proteasomes  were 
purified as  described  (51). A  purity of >90%  was  obtained as 
judged by Coomassie  staining.  Native proteasome  protein was 
quantified by UV absorption at 280 nm using an extinction coef- 
ficient of 1.0 cm2/mg. The yield was  150  p,g proteasome/5  X 
108 cells. 
Protease  Assays and HPLC Separation.  Fluorogenic substrate pep- 
tides Succ-LLVY-MCA,  Z-GGL-MCA,  VGR-MCA  03achem, 
Heidelberg, FRG) were prepared from 10-raM stocks in DMSO 
and incubated at several final concentrations for 1 h at 37~  with 
100  ng purified proteasome in 1 ml buffer containing 50  mM 
Tris/HC1, pH 7.5, 25 mM KC1, 10 mM NaC1,  1 mM MgC12, 
1 mM dithiothreitol, and 0.1 mM EDTA. The reaction was ter- 
minated by the  addition of 100  p,1  buffer containing 30  mM 
NaAc, pH 4.3,  100 mM CHzC1COOH, and 70 mM acetic acid. 
Fluorescence was  determined with  a  spectrofluorometer  (R.F- 
5001 PC; Shimadzu,  Duisburg, Germany) at 380 nm excitation/ 
440  nm emission.  The  Z-LLE-13NA  substrate  was  freshly  dis- 
solved for each  experiment, and the reaction was terminated by 
the addition of 1 vol ethanol. Measurements were performed at 
335 nm/410 nm. 
Digestion of a synthetic 25-mer peptide derived from the se- 
quence ofmurine CMV pp89 IE protein was carried out as previ- 
ously  described  (27). A  quantity of 20  la,  g  polypeptide (kindly 
provided  by  Dr.  P.  Henldein,  Humbolldt University, Berlin, 
Germany) was  dissolved  in 300  p,1  buffer  containing 20  mM 
Hepes/KOH (pH 7.8), 2 mM MgAc2, 1 nl_M  DTT, and digested 
with 1 or 2 I~g purified proteasomes  for 24 h at 37~  Cleavage 
products were analyzed by reverse phase HPLC: 50 p,1 of the di- 
gest were applied to a 4.6  X 250--mm Ultrasphere tKP18 column 
using equipment from Beckman (Munich, Germany). Products 
were eluted at a flow rate of 0.5 rrd/min with solutions A (water/ 
0.1% TFA) and B (acetonitrile/0.1% TFA): 0--5 rain, 0% B; 5-40 
rain linear increase to 60% B. Peaks were detected at 220 rim. 
Metabolic Labeling and Immunopredpitation.  Cells were  grown  to 
80% confluence and starved for 30 rain in methionine-free me- 
dium. They were labeled in methionine-free medium containing 
100-250  txCi/ml [3SS]methionine (Amershana International) for 
30 rain, washed with PBS, and chased for the indicated intervals. 
Immunoprecipitation of LMP2  and LMP7  has been previously 
described  (54). Immunoprecipitation  of class I molecules was car- 
tied out using the same procedure with the following modifica- 
tion: the lysis buffer contained 0.5% Triton X-100, 50 mM Tris, 
pH  7.5,  and  150  mM  NaC1. The  immunoprecipitates were 
washed with buffer containing 0.1% Triton X-100, 50 mM Tris, 
pH 7.5,  150 mM NaCI. For endo H treatment, immunoprecipi- 
rates were eluted by adding 25 Ixl of 50 mM Tris, pH 8, 1% SDS, 
and boiling for 5 rain. The samples were centrifuged and the su- 
pernatant was added to 25  Ixl of 50 mM citrate  buffer,  pH 5.5, 
containing 500  U  of endo H  (New England Biolabs,  Beverly, 
MA). The samples were incubated at 37~  for 18 h, followed by 
the addition of sample buffer.  All the buffers contained the fol- 
lowing protease inhibitors; 1 mM PMSF, 10 txg/ml aprotinin, 10 
btg/rnl leupeptin (Sigma Chemical Co., St. Louis, MO). The pre- 
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AP, x-ray films (Eastman  Kodak Co., Rochester, NY) were ex- 
posed to the dried gels. Bands were scanned with a densitometer. 
Western Blot Analysis.  Various  amounts of protein from total 
cell extracts (200 Izg) or purified proteasomes (5.0 p,g, 1.0 p,g, 0.2 
Izg, 0.04 Izg), prepared from "normal," EiAd5-transformed, and 
Ad12-transformed  cells, and  LMP-transfected  VAD12.79  cells, 
were  fractionated  on  15%  SDS-PAGE and  blotted  in  25  mM 
Tris/HC1 (pH 8.8)  +  0.19 M  glycine onto nitrocellulose  mem- 
branes  (Schleicher  &  Schuell,  Dassel, Germany).  Blots  were 
blocked for 1 h in buffer containing PBS, 5% (wt/vol) milk pow- 
der,  10% horse serum,  and 0.4% Tween 20, and incubated over- 
night  at  4~  with  antisera  directed  against  LMP2  (50),  LMP7 
(50), and a constitutive proteasome subunit,  MC3 (51), all diluted 
1:200  in  PBS/0.4%  Tween  20/2%  milk  powder.  Blots  were 
washed three times in PBS/0.4% Tween 20 and incubated for 1 h 
in goat anti-rabbit peroxidase  conjugate (Immunopr~iperate  Ber- 
lin,  Berlin,  Germany) diluted  l:1,000 in PBS/0.4% Tween/2% 
milk powder. The blots were washed four times  and x-ray films 
were exposed to the enhanced chemiluminescence-treated blots 
(Boehringer Mannheim). 
Nonequilibrium p  H  Gradient Electrophoresis  / PA GE  Two-Dimen- 
sional Gels.  TCA precipitates containing 50 p~g proteasomes were 
agitated  overnight in 60 I~l NEPHGE sample  buffer containing 
9.5 M urea, 2% NP-40, 5% ampholines (pH 3-10, Servalyt; Serva, 
Heidelberg,  Germany),  0.3% SDS,  and  5%  13-mercaptoethanol. 
Samples were applied  to the gel and run for 4 h at 400 V. After 
45  min  equilibration  in  25  ml  buffer containing  10% glycerol, 
10% [8-mercaptoethanol,  2.3% SDS, 90 M Tris/HC1, pH 6.8, the 
rod was  applied  to a  15% SDS-PAGE with  SDS  sample  buffer 
containing 1% agarose. The proteins were analyzed by Coomassie 
staining. 
Results 
Cell Smface Expression and Transport of Class I Molecules in 
an Ad12-Transformed Cell Line Stably Transfected with TAP1, 
TAP2, and TAP1 +TAP2 Expression Vectors.  We  previously 
characterized  a  panel  of Ad12-transformed  cell  lines  ex- 
pressing very low levels of class I antigens, comparing them 
with  EIAd5-transformed  and  normal  fibroblast  cell  lines 
(38, 55). We found that the expression of both the endoge- 
nous class I genes  (H-2K  b and H-2Db),  as well as that of a 
miniature  swine  class  I  transgene  (PD1),  were suppressed. 
The  reduced  levels  of H-2D  b  and  PD1  resulted  mainly 
from  their  inefficient  transport  to  the  cell  membrane,  a 
phenomenon  that  could  be  explained  by  the  limited 
amounts ofpeptides present in the EIL, and a  100-fold re- 
duction  in  the  steady  state  level  of TAP2  mlLNA  (31). 
However,  reexpression  of TAP2  in  an Ad12-transformed 
cell line  (VAD12.79) resulted 0nly in partial reconstitution 
of H-2D  b cell  surface  expression,  while  the  expression  of 
PD1 was comparable with that of the normal cell line (31). 
Fig.  1 A  compares the  cell surface  expression  of a  TAP2- 
transfected  clone  with  that  of a  TAPl-transfected  clone, 
and TAP1  +  TAP2-transfected clones. The FACS  |  analy- 
sis shows that TAP1  transfection did not affect the expres- 
sion  of class  I  antigens,  but  coexpression  of TAP1  and 
TAP2 enhanced by fourfold the  cell surface  expression  of 
H-D  b and by four- to sevenfold the  expression  of PD1  as 
compared to cells  transfected  with  TAP2 only. While  the 
expression  of PD1  was comparable or even exceeded that 
of the  normal cell line  M1,  the  expression  of H-2D  b was 
fourfold  lower.  Fig.  1  B  shows  the  steady  state  level  of 
TAP1  and TAP2 mP,  NA in mixed populations of TAP1- 
and TAPl+TAP2-transfected  cells  (lanes  4 and  5, respec- 
tively), and randomly selected TAP-transfected clones, ex- 
pressing  either  TAP1  (C1.5),  TAP2  (C1.1),  or both  (C1.7 
and C1.9).  As depicted in the figure the steady state level of 
TAP1  and TAP2 mRNA  in the TAP-transfected cell lines 
was significantly higher than in the normal cell line M1  or 
the E1Ad5-transformed cell line A505, indicating that the 
level of TAP mRNA is not limiting in the transfected cells. 
To  further  locate  the  defect  in  TAP-transfected  cells, 
egress  of class  I  molecules  from the  ER  was  analyzed by 
their  endo  H  resistance  acquisition  in pulse-chase  experi- 
ments  (Fig.  2).  The transport  rate  of PD1  (A)  and H-2D  b 
(B)  was  studied  in  MI,  VAD12.79,  and  TAP-transfected 
cell  lines.  To  differentiate  between  empty  and  peptide- 
loaded class I molecules, antibodies directed against an epi- 
tope on the &l  domain  (B22.249)  (Fig. 2  C') or on the c~3 
domain (28.14.8)  ofH-2D b (Fig. 2 B) were used for immu- 
noprecipitation.  The results show (Fig. 2, A  and/3) that the 
rate  of endo  H  resistance  acquisition  of PD1  was  indeed 
comparable in the  TAP-transfected and in the normal cell 
lines,  and  that  the  observed  reduction  in  cell  surface  ex- 
pression  of H-2D  b was directly correlated with  the  ineffi- 
cient transport of these molecules through the Golgi appara- 
tus.  However,  10-20%  of the  H-D  b molecules  (Fig.  2  C, 
inset), which were recognized and immunoprecipitated  by 
the  conformation-dependent  otl  antibody  (B22.249),  ac- 
quired endo H  resistance in TAP-transfected cells (Fig. 2  (5). 
These H-2D  b molecules presumably accumulate on the cell 
surface and are detected in FACS  |  analysis.  These data,  in 
conjunction  with  the  results  of the  FACS  |  analysis  of 
TAP-transfected  Ad12-transformed  cells,  support  the  no- 
tion  that  although  expression  of  TAP2  in  Adl2-trans- 
formed cells  is essential,  additional factors are necessary for 
obtaining  efficient  transport  and  maximal  cell  surface  ex- 
pression of the endogenous class I molecules. 
TAP-independent Inhibition qf Class I Molecule Transport in 
Ad12-transformed Cells.  The kinetics of assembly and trans- 
port of the class I complex depends on the relative amounts 
of the  heavy chains  and  132m  (56,  57).  The likelihood  of 
limited  amounts  of [32m  interfering  with  stable  assembly 
and transport of the class I complex was ruled out in view 
of the finding that the expression of high levels of 132m in 
TAP-transfected  Ad12-transformed  cells  via  recombinant 
vaccinia  viruses,  or  the  addition  of recombinant  [32m  to 
cell  extracts,  did  not  enhance  assembly  or  transport  of 
H-2D b (data  not  shown).  To  exclude  the  possibility  that 
endogenous class I molecules were being produced in lim- 
iting  amounts,  we  analyzed  the  transport  of H-2D  a pro- 
duced by recombinant vaccinia viruses.  As can be seen  in 
Fig.  3  A,  there  was  inefficient  transport  of H-2D  a mole- 
cules through  the  Golgi in VAD12.79 and in  TAP-trans- 
fected VAD12.79 cells.  These results  are comparable with 
the results obtained for the endogenous H-2D  b. Moreover, 
when  VAD12.79 was infected  with  recombinant  vaccinia 
502  Peptide Transporter  and LMP Molecules in Adenovims-transfonned Cells Fignre 1.  Expression  of class I antigens in TAP-transfected Ad12-transformed cell lines. (A) Cell surface expression of class I antigens on the normal 
cell line (MI), Ad12-transformed cell line (VAD12.79), TAPl-transfected VAD12.79 (CI.5), TAP2-transfected VAD12.79 (CI.  1), TAP1  +2-transfected 
VAD12.79 (CI.  7, CI.9) was analyzed by immunofluorescence staining with the following antibodies: PT85A (anti-PD1) (arrowhead),  20.8.4S (anti-H- 
2K  b) (--), and 27.11.13 (anti-H-2D b) (narrow arrow). Second antibody control (fat arrow). CI, individual clone. (B) Northern  analysis  of mRNA from 
TAP-transfected VA12.79 and control cell lines (M1, A505,  VAD12.79, VAD12.79-Neo) was carried out using 20 I.Lg  of cytoplasmic  RNA which was 
fractionated on a formaldehyde/formamide agarose gel, transferred to nylon membrane, and hybridized as described in Materials and Methods with 
probes  specific for  TAP1,  TAP2,  and  actin.  VADI2.79-TAP1(b),  VAD12.79-TAP1+2(b):  mixed  cell populations transfected with  TAP1 and 
TAP1 +TAP2, respectively. C1, individual clone. 
viruses expressing the human TAP1 +TAP2 genes, the trans- 
port of PD1  was reconstituted (Fig. 3  B) but there was no 
change in the transport of H-2D a molecules expressed from 
a coinfected recombinant vaccinia virus (data not shown). 
To determine whether H-2 molecules can acquire endo 
H  resistance, and to  rule out any negative effect on trans- 
port of endogenous proteins possibly caused by the vaccinia 
virus infection, cells were treated with ~/-IFN before vac- 
cinia  infection.  Since  H-2K  b  gene  transcription  is  sup- 
pressed in these cells, recombinant vaccinia viruses that en- 
code either H-2K  b or H-2D a were used for infection. Fig. 
4  demonstrates  that  "y-IFN treatment  resulted in  two-  to 
threefold enhancement of H-2 transport, so that the rate of 
acquisition of endo H  resistance was comparable with that 
observed  in  EIAd5-transformed  cells.  Comparable  results 
were  obtained  with  cells  pretreated  with  ~/-IFN  and  in- 
fected with recombinant vaccinia viruses expressing H-2K  b 
or H-2D  a molecules (Fig. 4, A  and B). 
Since these results indicated that infection with vaccinia 
viruses  for  60-90  min  does  not  generally  interfere  with 
transport of class I molecules, it is conceivable that there is a 
selective inhibition  in  the  transport  of H-2  class  I  mole- 
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cules,  but  not  of PD1,  in  TAP-expressing  Adl2-trans- 
formed cells. The results also suggest the involvement of a 
factor(s)  that  is  regulated  by  ~/-IFN  and  can  induce  the 
transport  of these  molecules.  Since  ~/-IFN  induces  LMP 
transcription  and  thus  affects  the  production  of selective 
sets ofpeptides (23-27), we next addressed the level ofpro- 
teasome-associated LMP2 and LMP7 subunits and the pro- 
teolytic  activities  mediated  by  purified  20S  proteasomes 
prepared from these cell lines. 
Expression  of LMP2  and  LMP7  Molecules  in  Ad12-  and 
EIAd5-transformed  CelI Lines.  To  determine  the  steady 
state level of LMPs and their inducibility by ~/-IFN, as well 
as the level of proteasome-associated LMPs in Ad12-trans- 
formed cells, both crude cell extracts (which may also con- 
tain unprocessed proteasome precursors  [58]),  and purified 
20S proteasomes were fractionated on SDS gels and hybrid- 
ized with antibodies specific for LMP2 or LMP7. Whereas 
LMP2 and LMP7 were expressed in the crude cell extracts 
and in purified 20S proteasomes from normal and EIAd5- 
transformed cell lines, they were hardly detectable in simi- 
lar preparations from Ad12-transformed cell lines  (Fig.  5, 
A  and  B).  Nonetheless,  ~/-IFN induced the  expression of Figure 2.  Transport of PD1,  but not of H-2D  b,  is reconstituted in 
TAP-transfected  Ad12-transformed  cell  line.  Normal  cell  line  (M1), 
Ad12-transformed cell line  (VAD12.79), TAP2-transfected VAD12.79 
and TAP1 +TAP2-transfected VAD12.79 cells were metabolically  labeled 
with  [3SS]metbionine  for 30 rain and chased as indicated in the figure. 
Immunoprecipitations were carried out with antibodies directed against 
PD1  (A), using PT85 antibody; H-2D  b (B), using an anti-or3 antibody 
(28.14.8); and H-2D  b (C), using an anti-od antibody (1322.249). The im- 
munoprecipitates were treated with endo H. X-ray films were scanned by 
densitometer. The percentage of endo H-resistant forms was calculated 
and is presented graphically (A and C). The inset in C depicts the per- 
centage of  molecules immunoprecipitated by the anti-H-2D  b ~xl antibody 
(B22.249) in VAD12.79 and TAP-transfected VAD12.79, using immu- 
noprecipitations observed in the E1Ad5-transformed cell line (A505) as 
the basis. Endo H R, endo H resistant; Endo H  s, endo H sensitive; *non- 
specific band. 
LMP2  and  LMP7  in Adl2-transformed and  in  the  TAP- 
transfected Ad12-transformed cell lines (Fig. 5 A). In y-IFN- 
treated cells the level of LMP2 was comparable to that ob- 
served in untreated M1  and A505  cells, while the level of 
LMP7  was fourfold lower.  In addition, an additional band 
which  may  be  an  LMP  precursor  could  be  detected  in 
crude  extracts from y-IFN-treated cells. Since application 
of purified 20S proteasomes (Fig. 5  B)  allowed us to cover 
a  protein  range  of >100-fold,  the  results  clearly indicate 
that  the  Ad12-transformed  cell line,  VAD12.79,  contains 
>100-fold  less  LMP2  and  LMP7  than  the  E1Ad5-trans- 
formed  cell line  A505.  On  the  other  hand,  the  level of 
MC3, which is a constitutive proteasome o~ subunit (Fig. 5 
/3)  and  of the  8  subunit  (visualized  by  cross-reaction  of 
anti-LMP2  antibodies with  the  8  subunit),  were  identical 
in both Ad12 and E1Ad5-transformed cell lines. 
Assuming  that  the  unidentified  bands  observed  in  the 
hybridization with  anti-LMP2  and  anti-LMP7  antibodies 
(marked  by  stars  in  Fig.  5  A)  might  be  LMP  precursors 
produced both in VAD12.79 and A505, but not processed 
to  the  mature  protein  in  VAD12.79,  pulse-chase  experi- 
ments  were  carried out  using  antibodies against LMP7  to 
immunoprecipitate LMP7  and  LMP7  precursors.  The  as- 
says  revealed that  the  30-kD  LMP7  precursor  was  being 
synthesized by A505  but not by VAD12.79.  Processing of 
LMP7  by A505  was  normal,  as the precursor was  chased 
into the mature 23-kD after 4  h  (data not shown). 
The  dramatic  differences between  LMP  levels in Ad12 
and EIAd5-transformed cell lines prompted  us  to  investi- 
gate  whether  the  level  of other  components  of the  20S 
proteasome also varied.  A  two-dimensional PAGE  of 20S 
proteasomes  from  VAD12.79  and  A505  is  presented  in 
Fig.  6.  As  can  be  seen,  all  the  20S  proteasome  subunits, 
aside  from  LMP2  and  LMP7,  were  expressed  in  equal 
amounts in the Ad12-transformed cell line.VAD12.79  and 
the E1Ad5-transformed cell line A505.  In A505,  the dis- 
tribution of the replaceable subunits was 16% LMP2/84% 8 
and 34% LMP7/66% MB1. These results are identical with 
those obtained in another fibroblast cell line, B8  (data not 
shown). 
Downregulation of LMP2 and  LMP7  in Ad12-transformed 
Cells.  Since  the  level of LMPs  can  be  regulated both  at 
the transcriptional and at the posttranscriptional levels (51), 
the steady state level of LMP2  and LMP7  was determined 
in  a  panel  of Ad12-transformed  cells  (Fig.  7).  The  steady 
state level of both LMP2 and LMP7 mP,.NA was undetect- 
able in  most  Ad12-transfomled  cell lines and  reduced  by 
fourfold  in  VAD12.20.  The  steady  state  level  of  both 
LMP2 and LMP7 mRNA  was 20-fold lower in Ad5-trans- 
formed and normal fibroblast cell lines (ME1, A505, A501, 
M1)  than in a T  lymphoma cell line (PDI.1). These results 
are in full agreement with the Western blot analysis and the 
immunoprecipitation  data,  which  revealed  that  both  the 
LMP precursors and the LMPs are absent from Ad12-trans- 
formed cells. 
Proteasoma! Peptide Hydrolyzing  Activities  of 20S  Protea- 
somes  from  VAD12.79 and A505.  Since secondary modi- 
fications and the exchange ofsubunits in the proteasome, as 
observed in y-IFN-treated cells, often results in changes in 
enzymatic properties (23-27), we explored the in vitro en- 
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molecules encoded  by recombi- 
nant vaccinia virus is inefficient 
in TAP-transfected and in VAC- 
TAP-infected Ad12-transformed 
cells. TAP-transfected  cell lines 
and control cell lines (A505 and 
VAD12.79) were infected for 60 
rain (B) or 90 rain (A) with re- 
combinant  vaccinia viruses ex- 
pressing H-2D  a  (A)  or  human 
TAPI+TAP2 (/3) or with wild- 
type vaccinia virus (WR) (B).  Af- 
ter pulsing, the cells were chased, 
and class I  molecules were  im- 
munoprecipitated  and  treated 
with endo H as described in the 
legend to Fig. 2. The following 
antibodies were used for immu- 
noprecipitation;  anti-H-2D  d ~x3 
(34.2.12) in A, anti-PD1  (PT85) 
in  B,  anti-VAC  protein  in  B. 
X-ray films were scanned by densitometer, and the percentage ofendo H-resistant forms was calculated and is presented graphically in A. The absence of 
signal in TAP1-VAD12.79  at 0 rnin chase was due to technical problem with vaccinia infection. Endo H p', endo H resistant; Endo H s, endo H sensitive; 
*nonspecific band. 
zymatic  activities  of purified  20S  proteasomes  from  the 
Ad12-  and  E1Ad5-transformed  cell  lines.  The  chymo- 
trypsin-like and the trypsin-like activities were assayed dur- 
ing standard fluorogenic peptide  substrates with Tyr,  Arg, 
Leu, and Glu at the P1  position. Fig. 8  clearly demonstrates 
that  the  cleavage  of Leu  and  Tyr  peptides  (the  chymo- 
trypsin-like activity), but not of Arg (the trypsinqike activ- 
ity),  was  lower in A505  than in VAD12.79.  Comparable 
reduction in chymotrypsin-like activity was documented in 
mouse  embryonal fibroblasts  after  treatment  with  ",/-IFN 
and  incorporation  of LMP2  and  LMP7  into  the  protea- 
some  (27).  These  data  suggest  that  transformed  cells  ex- 
pressing very low levels of LMPs may differ in their capac- 
ity to generate constitutively certain sets of peptides. 
Distinct  Cleavage  Site  Preference of 20S  Proteasomes from 
VAD12.79 and A505.  Although fluorogenic pep  fide  sub- 
strates are suitable for characterizing different proteolytically 
active sites of latent and active 20S proteasomes,  they pro- 
vide  little  information  on  how  proteasomes  react  with 
larger polypeptides  which  represent in vivo substrates.  To 
determine the capacity of VAD12.79 and A505  to hydro- 
lyze a larger polypeptide, the synthetic pp89  25-mer poly- 
peptide,  which harbors an antigenic nonamer peptide  (27), 
was  subjected  to  cleavage  by  purified  proteasomes  from 
these cell lines. After complete substrate turnover, the pro- 
cessing products generated from the 25-mer polypeptide by 
incubation with 20S proteasomes were separated on reverse 
phase HPLC  (Fig. 9). A  comparison of the chromatographs 
indicates that the absence of LMP subunits caused a signifi- 
cant  quantitative  difference  in  at  least  some  fragments 
(ILT25.71,  27.81,  29.53,  33.19,  34.44).  It is clear that  the 
cleavage  specificity  of the  proteasomes  in  both  cell  lines 
was  identical  although  in  VAD12.79  there  was  a  higher 
concentration of the  most  prominent peptide  (P,.T33.19), 
and reduced  amounts of at least three  other peptides.  The 
same results were  obtained whether  1  or 2  Ixg proteasome 
preparation  was  used,  indicating that  digestion  was  com- 
plete and that the observed differences were not due to in- 
complete  hydrolysis  of the  25-mer  polypeptide  substrate. 
The  results  of both  enzymatic  assays  demonstrate,  there- 
Figure  4.  Transport  of H-2D  a  and 
H-2K  b  encoded  by  recombinant vac- 
cinia viruses is enhanced after pretreat- 
ment  of Ad12-transformed  cells with 
y-IFN.  TAP-transfected  cell lines  and 
control cell lines (A505 and VADI2. 79) 
were infected for 60 rain (A) or 90 min 
(B)  with  recombinant vaccinia  viruses 
expressing H-2K  b (A)  and H-2D  d (/3). 
The  cells were  treated  with  100  U 
~/-IFN for  48  h  before  vaccinia infec- 
tion. After pulsing the ceils were chased, 
and class I molecules were imnmnoprecipitated  and treated with endo H as described in the legend to Fig. 2. The following antibodies were used for im- 
munoprecipitation:  anti-H-2K  b ~1/ct2 (20.8.4S) in A and anti-H-2D  d cd/ct2 (34.5.8) in (B). X-ray films were scanned by densitometer, the percentage 
of endo H-resistant forms was calculated and is presented graphically in B. Endo H p', endo H resistant; Endo H s, endo H sensitive. 
505  Rotem-Yehudar et al. Figure  5.  Expression of LMP2 and 
LMP7 molecules is suppressed in Ad12- 
transformed cell lines but is induced by 
"/-IFN. Total cell extracts (A) and indi- 
cated amounts of purified 20S protea- 
some  extracts  from  VAD12.79 and 
A505  (B)  were fractionated by SDS- 
PAGE and analyzed for the expression 
of LMP2, LMP7, and MC3 by hybrid- 
ization of Western  blots with aflqnity 
purified antisera. Extracts from the fol- 
lowing cell lines were analyzed before 
and  after treatment with "/-1FN: M1, 
A505, VAD12.79, VAD12.42, TAPI + 
TAP2-transfected  VAD12.79 (A).  A 
cross-reaction with the 8 protein is indi- 
cated. *Unidentified band. 
fore,  that  proteasomes  prepared  from  VAD12.79  and 
A505  differ in the frequency at which they cleave specific 
sites in the pp89 polypeptide. 
Reexpression  of  LMP2  and  LMP7  in  TAP-reconstituted 
Ad12-transformed  Cells Enhances but Does Not Completely Re- 
store the Expression of rio2 Class I Molecules.  To  determine 
whether  reconstitution  of LMP  expression  could  restore 
transport  and  cell  surface  expression  of class  I  genes,  a 
TAPl+TAP2-transfected  VAD12.79  cell line  was further 
transfected  with  plasmid  constructs  expressing  LMP2  and 
LMP7. Fig. 10 shows the LMP levels in the mixed population 
and  three  individual  clones  that  express  both  LMP2  and 
LMP7.  The  clones  showed  levels  of LMP2  and  LMP7 
which were significantly higher than that of M1  or A505. 
FACS  |  analyses of class I cell surface expression of LMP2+ 
LMP7-expressing  clones  or  of the  mixed  populations  is 
shown in  Fig.  11.  The  figure shows  that LMP expression 
enhanced  cell  surface  expression  of the  class  I  antigens. 
However,  while  the  expression  of PD1  was markedly en- 
hanced such that the mean fluorescence~cell increased by at 
least  twofold,  the  expression  of H-2D  b was  increased  by 
1.2-1.7-fold and was still  two- to threefold lower than that 
of a normal cell line. These results correlated with transport 
efficiency of these molecules as analyzed by pulse-chase ex- 
periments  (data not shown). 
Discussion 
MHC  class  I molecules are a family of highly polymor- 
phic cell surface glycoproteins whose primary function is to 
bind and present foreign peptides to CTL (1,  7, 8), thereby 
controlling  pathogenic  infections  and  tumor  progression 
(2-4).  Cumulative  recent  data  attest  to  the  fact  that  sup- 
pression  of class  I  cell surface expression  involves interfer- 
ence with  the transit  of these molecules to the  cell surface 
of certain tumor cells  (30-33).  Several human tumors, such 
as cervical carcinomas, lung carcinomas, and Burkitt's lym- 
phomas  demonstrate  direct  correlation  between  reduced 
levels of class I antigens, escape from CTL recognition, and 
tumor progression.  Murine  tumors transformed by adeno- 
viruses  have  served  as  excellent  experimental  model  sys- 
tems for proving that escape from immune  recognition in 
vitro  and  in  vivo  is  at  least  in  part  due  to  suppression  of 
class I expression (5, 37, 59, 60). In addition, since these tu- 
mors are transformed in vitro,  the reduced levels of class  I 
antigens do not result from in vivo selection of class I nega- 
tive  cells  as  probably  occurs in  human  tumors.  Thus,  the 
tumor cell lines  described in  our present  study are  appro- 
priate models for studying active suppression caused by ei- 
ther  viral  proteins  or  cellular  proteins  induced  by  viral 
transformation.  Mechanisms involved in regulation of class 
I  molecule  expression  have  been  analyzed  in  parallel  in 
Adl2-transformed, in Ad5-transformed, and in normal cell 
lines,  all originating from the same pool of parental embry- 
onal fibroblasts  (31,  55, and the present study). Since Ad5- 
transformed  and normal cell lines  exhibit  normal levels  of 
class  I antigens and are not tumorigenic in vivo, they pro- 
vide adequate controls for Ad12-transformed cell lines. 
In the present  study and in our previous report  (31)  we 
demonstrated  that in Ad12-transformed  cell lines,  the  ex- 
pression  of most  genes  definitely  associated  with  antigen 
processing  and  presentation  is  differentially  reduced.  Ac- 
cording to the degree of suppression,  these genes can be di- 
vided  into  two  groups:  The  first  includes  TAP2,  LMP2, 
and LMP7,  which  exhibit  a  >100-fold reduction  in  their 
encoded steady state mRNA  levels, with both mRNA  and 
protein  products  barely  detectable.  The  second  group in- 
cludes TAP1, class I heavy chains, and [32m genes showing 
506  Peptide  Transporter  and LMP Molecules in Adenovirus-transformed  Cells Figure  6.  Analysis of  20S  proteasome  subunits from  A505  and 
VAD12.79 cells. Isolated 20S proteasomes from A505 and VAD12.79 
cells were analyzed  by nonequilibrium two-dimensional gel electrophore- 
sis. LMP2, LMP7, MB1, and the 8 subunits are marked with arrows. 
a  2-10-fold  reduction  in  their  steady state  mRNA  levels, 
with  gene  expression  varying among individual  cell  lines. 
The data suggest that there is at least one common regula- 
tory element  which  controls  transcription  of these  genes, 
and  is  affected  by  viral  transformation.  Nonetheless,  it  is 
clear that  the  contribution  of this  yet unidentified  regula- 
tory element to the transcription  efficiency of the different 
genes varies,  resulting  either in complete  or partial  reduc- 
tion in their  transcription.  The EIA-encoded proteins  are 
involved  in  interactions  among  various  nuclear  proteins, 
and can either enhance or suppress gene transcription  (61). 
Since  adenovims-transformed  cells  express  high  levels  of 
these proteins  (data not shown), it is conceivable that they 
are  involved  in  the  downregulation  of genes  associated 
with  antigen  processing  and  presentation.  The  possibility 
that  multiple  suppressive  mechanisms  affect  the  transcrip- 
tion  of the various  genes via different  regulatory elements 
cannot be ruled out.  However, it seems less  likely in view 
of the fact that all the genes described above are destined to 
function  in  antigen  processing  and  presentation  and  it  is 
more conceivable that they are regulated by common ele- 
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Figure 7.  Steady  state levels of LMP2 and LMP7 mP-NA are reduced 
in  Ad12-transformed cells. Northern  analysis of mP,  NA from normal 
(M1),  E1Ad5-transformed (A505, A501),  Ad5-transformed (ME1), 
Ad12-transforrned (VAD12.79,  VAD12.42, VAD12.20, VAD12.36, 
VAD12.25) cell lines and the RadLV-transformed  thymoma (PD1.1)  was 
carried out as described in the legend to Fig. 2 B. The P,  NA was hybrid- 
ized with probes specific for LMP2, LMP7, and Actin as indicated in the 
figure. 
ments.  In addition,  the class  I heavy chain,  TAP and LMP 
genes are located in  the  MHC  locus,  and therefore  could 
have evolved from a  common ancestral gene and maintain 
common associated sequences. 
Adl2-transformed cells are the first murine tumor system 
described  where  both peptide  transporter  and LMP  genes 
are  downregulated  as  a  result  of a  transformation  event. 
P,.estifo  et al.  (30) previously identified human cancers with 
defective  antigen  processing,  which  do  not  express  TAP 
and LMP mRNA.  However,  the investigators did not de- 
termine whether this deficiency was the result of the trans- 
formation event, since the extent of the processing capacity 
and peptide  transporter  expression in the normal counter- 
parts of these cell lines was not established.  We now show 
that both sets  of genes are expressed in  the parental  fibro- 
blasts and in Ad5-transformed cells  that originated from the 
same  pool  of embryonal  fibroblasts,  thereby  establishing 
that suppression of these genes is clearly associated with the 
transformation  event.  Moreover,  we  have  confirmed  that 
expression  of TAP  genes  is  essential  to  the  expression  of 
class I antigens in this system (31, and Fig.  1 A). The latter 
conclusion  is  in  agreement  with  data  obtained  in  TAP- 
negative  mutant  cell  lines  such  as  RMA/S  and  LBL 
721.174,  where  transfection  of TAP  genes  reconstitutes 
class  I  expression  and  antigen  presentation  (7,  8,  12,  13). 
However,  we now find that reexpression  of TAP genes is 
essential but not sufficient for restoration of maximal class I 
molecule expression.  In TAP-transfected Ad12-transformed 
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Figure  8.  Peptide hydrolyz- 
ing activities of 20S proteasomes 
from A505 and VAD12.79 cells. 
Hydrolyzing activities of 10  txg 
20S  proteasomes isolated from 
VAD12.79 (D)  and  A505  (￿9 
were assayed by  using fluoro- 
genic subswates at a range of  0--250 
IxM.  The  following substrates 
were  used: Succ-LLVY-MCA 
(chymotrypsin-like) Z-GGL-MCA 
(chymotrypsin-like);  Bz-VGR- 
MCA  (trypsinqike); d)Z-LLE- 
13NA (PGPH). 
was completely restored, but the expression of H-2D  b was 
only partially reconstituted (Fig. 1 A). Moreover, metabolic 
labeling of these  cells followed by chase and immunopre- 
cipitation (Fig. 2)  revealed that most H-2D  b molecules did 
not  acquire  endo  H  resistance  over  a  long  chase  period. 
The same results were obtained with cells infected with re- 
combinant  vaccinia  viruses  expressing  human  TAP1  and 
TAP2 molecules  (Fig,  3  B).  Since the  assembly and trans- 
port of a stable class I complex is dependent upon each of its 
components  (49,  57), we tested whether limiting amounts 
of either  132m or class I heaw chains would interfere with 
these processes in TAP-transfected or VAC-TAP-infected 
Ad12-transformed cells.  Infection with a recombinant vac- 
cinia virus  expressing human  [~2m,  or the  addition  of re- 
combinant ~2m to cell extracts,  did not enhance assembly 
or  transport  of H-2D  b  (data  not  shown).  Infection  with 
vaccinia  viruses  expressing  H-2D  d and  H-2K  b  (Figs.  3  A 
and  4  A)  revealed  that  fully  conformed  molecules  were 
transported  to  the  cell  surface  as  efficiently as  in  EIAd5- 
transformed  cells.  However,  similarly  to  the  results  ob- 
tained for H-2D  b, only a small fraction (10-20%) ofH-2D d 
molecules acquired a conformation allowing efficient trans- 
port to the cell surface.  This implies the necessity for additional 
factor(s).  Treatment  of TAP-transfected  Ad12-transformed 
cells  with  y-IFN  before  infection  with  the  recombinant 
vaccinia virus resulted in enhanced transport of H-2D  d and 
H-2K  b  (Fig.  4).  These  data  can  be  explained  as  follows: 
First,  since the third component of the class I complex is a 
peptide,  it  is  plausible  that  the  amount  of selective  sets  of 
peptides  (with  high  binding  affnity  to  H-2  molecules)  is 
limiting in TAP-transfected cells,  despite the overexpression 
ofpeptide transporter genes. Second, the rate of transport of 
different  class  I molecules  through  cell  organelles  depends 
on their conformation,  and is determined by polymorphic 
amino  acid residues  in the ~xl/ot2  domain  (62-65).  A  spe- 
cific differential  effect on transport of human class I mole- 
cules was recently demonstrated in HSV-infected cells  (66). 
It is likely that class I molecules, by acquiring various con- 
formations during biosynthesis and assembly, display a range 
of affinities  in  their  association  to  chaperons  such  as  cal- 
nexin and BiP  (67, 68).  It is conceivable that alterations in 
the amount,  affinity to class  I heavy chains,  or function of 
such  chaperons  in  Ad12-transformed  cells  could  differen- 
tially affect the transport  of these molecules.  It bears men- 
tion that one of the chaperons (gp96), which binds peptides 
and  may be  involved  in  antigen  presentation  (69),  is  in- 
duced by y-IFN, a treatment  that facilitated  the  transport 
of H-2 molecules in our experiments. 
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Figure  9.  Quantitative  differences  in 
cleavage products ofpp89 25-met polypep- 
tide  by  20S  proteasomes prepared  from 
VAD12.79 and A505 cells. The pp89 25- 
mer substrate was incubated in the presence 
of20S proteasomes  from A505 or VAD12.79 
cells. After complete turnover  of the sub- 
strate, the peptide mixture was separated by 
reverse phase HPLC.  The  peptide  region 
(retention  time  20-35  rain)  of  original 
chromatographs are shown.  Peaks exhibit- 
ing an over twofold difference between the 
cell lines are marked with a star. AU, absor- 
bance units. 
Our  data  demonstrate  a  direct correlation between  the 
inhibition in transport of H-2 molecules and the total sup- 
pressed expression of LMP2 and LMP7. Ad12-transformed 
cells were  totally devoid  of LMP2  and  LMP7  molecules 
(Figs.  5-7),  resulting  in  quantitative  alterations  in  pro- 
teolytic activities mediated by the 20S  proteasomes prepa- 
rations from these cells (Figs. 8  and 9).  ~/-IFN, which  in- 
duces LMP expression, also induced the efficient transport 
of the H-2 molecules expressed by a recombinant vaccinia 
viruses in TAP-transfected cells. Since both TAP and H-2 
heavy chains were overproduced in these cells, it is feasible 
that the induction of LMPs or another unidentified factor 
which is interferon regulated resulted in enhanced transport 
of H-2 molecules. It should be emphasized that the inhibi- 
tion  of H-2D b  transport  in  TAP-transfected  Adl2-trans- 
formed cells is comparable with the selective and inefficient 
antigen presentation by H-2D b molecules reported by Van 
Kaer et al. in LMP2 mutant mice (70) and by Cerundolo et 
509  Rotem-Yehudar et al. Figure  10.  Expression  of LMP2 and LMP7 in LMP-transfected  cells. 
Western analysis of cell extracts from LMP-transfected  TAP-reconstituted 
VAD12.79  (12.79/T/LMP)  (mixed transfectants)  or  individual clones, 
and control cell lines (M1,  A505,  TAP-reconstituted puromycin-trans- 
fected VAD12.79  [12.79/T/Control])  was  carried out using  100  Ixg of 
protein (as determined by Bradford assay) and antibodies against LMP2 
and LMP7 as described in the legend to Fig. 5 A. C1, individual clone. 
al. in LBL 721.174  cells transfected with peptide transporter 
genes  (29). 
There  are several indications that LMP2  and LMP7  play 
a  role in antigen processing and regulate proteasome-medi- 
ated  proteolytic  activities  (23-27).  However,  the  observa- 
tions that  in human  cell lines lacking LMPs  but with pep- 
tide  transporters  reconstituted  by  transfection,  normal  cell 
surface levels of class I  MHC  are expressed,  and these  cells 
are  able to  present  most  antigens  (71-73),  suggest  that  the 
absence  of LMP2  and  LMP7  do  not  limit  the  supply  of 
peptides  for  antigen  presentation  by  class  I  molecules,  at 
least not in  these  cells.  Nevertheless,  several recent  reports 
imply that  the  expression  of LMPs  is  essential  to  efficient 
presentation of selective sets ofpeptides  (28, 29, 70) and for 
maximal  expression  of class  I  antigens  (28).  Most  studies 
minimizing  the  role  of LMPs  for  class  I  expression  either 
used  cells of lymphoid  origin  (71-73)  or tested  cell surface 
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Figure  11.  Expression  of class I antigens 
in  LMP-transfected  TAP-reconstituted 
Ad12-transformed  cell  lines￿9 Cell  surface 
expression of class I antigens on the normal 
cell  line  (M1),  TAP-reconstituted  Ad12- 
transformed  cell line transfected with puro- 
mycin-resistance  gene  (12.79/T/control),  or 
cotransfected  with  LMP2+LMP7  (mixed 
transfectants, MIX; individual clones, C1.13, 
C1.17)  were  analyzed  by immunofluores- 
cence staining  with the following antibod- 
ies:  PT85A  (anti-PD1);  (arrowhead), and 
27.11.13  (anti-H-2D  b)  (narrow arrow). Sec- 
ond antibody control (fat arrow). C1, individ- 
ual clone. 
510  Peptide Transporter and LMP Molecules in Adenovirus-transformed Cells cells  originating  in  LMP  knockout  mice  (28,  71).  How- 
ever, the effects of LMP deficiency on the constitutive  ex- 
pression  and  transport  of class  I  molecules  in  other  cells 
have  not  been  analyzed in  detail.  It is possible  that LMP2 
and LMP7  play a  more critical role in the  constitutive  ex- 
pression  of class  I  molecules in fibroblasts and possibly also 
in other cells not of lymphoid origin.  This is entirely likely 
since lymphoid cells express higher levels of peptide  trans- 
porter genes (data not shown),  and perhaps additional cyto- 
solic  proteases  that  may  be  used  for  antigen  processing. 
Moreover,  Brown  et al.  (74)  reported that proteasomes are 
structurally diverse, and can exist in several distinct compo- 
sitions  within  mammalian  tissues  and  cell lines  and  conse- 
quently, may carry out diverse proteolytic activities. Differ- 
ences  between  lymphocytes  and  fibroblasts  in  proteasome 
composition could result, therefore, in quantitative and quali- 
tative  differences  in  peptide  production  between  the  two 
cell types. In transformed cells where only small amounts of 
the total peptides  are tumor-associated  antigens,  alterations 
in  cleavage specificities as a  result  of LMP2/LMP7  down- 
regulation  might  completely  abolish  their  generation  and 
hence their recognition by the immune system. 
To  determine  whether  LMP2  and  LMP7  deficiencies 
could account for the downregulation  of expression of class 
I  molecules  in Ad12-transformed  cells,  TAP-reconstituted 
Ad12-transformed  cells  were  transfected  with  LMP2  and 
LMP7 genes.  High  stable  expression  of LMP2  and  LMP7 
were  obtained  (Fig.  10)  that  resulted  in  enhancement  of 
cell  surface  expression  of PD1  and  H-2D  b  (Fig.  11).  De- 
spite the fact that the transfected cell lines expressed at least 
10-fold higher levels of TAP and LMP molecules, transport 
and  cell surface expression  of H-2D  b did not reach that of 
normal  cell  lines  or  E1Ad5-transformed  cell  lines.  These 
data,  supported  by  the  fact  that  even  in  the  presence  of 
high levels of class I  and TAP molecules full restoration  of 
class  I  transport  could  only  be  achieved  by ~/-IFN  treat- 
ment  (Fig.  4),  suggest the  existence  of an additional  factor 
that plays a  role in stabilization  and  transport  of the  class  I 
complex,  and  that the expression  or function  of this factor 
is  IFN regulated.  The  expression  of the  29-kD  subunit  of 
the  ~/-IFN-inducible  11S  regulator  of the 20S  proteasome 
cannot  account  for the  difference  in MHC  class  I  expres- 
sion as it is equally apparent in Northern and Western anal- 
yses in  the  VAD12.79  and A505  cell lines  (Soza,  A.,  un- 
published results). 
The  cell lines  described  in  this  study are so far the  only 
murine  cells in which  both LMP2  and LMP7  are knocked 
out  as a  result  of a  transformation  event.  A  previously de- 
scribed hepatoma cell line (74) that does not express LMP2 
was  used  to  analyze  and  characterize  distinct  proteasome 
subsets. However, it is probable that this cell line represents 
normal  hepatocytes  and  does  not  reflect  a  specific  case  of 
LMP2  downregulation  resulting  from  malignant  transfor- 
mation.  Adenovirus-transformed  cell  lines  are  unique  in 
that  patterns  of  gene  regulation  can  be  compared  with 
those  of the  normal  parental  cells  and  as  shown  in  this 
study,  may be  used  for the  identification  of novel  factors 
that play a  role in  class I  transport  and  in  antigen  process- 
ing.  Such  cell lines  are also valuable  tools for studying the 
transcriptional  regulation  of peptide  transporter  and  LMP 
genes,  and  for further  analyses  of proteasome  subunits  as- 
sembly as well as the class I complex assembly and transport 
in normal and transformed cells. 
Our  results  indicate  that  suppression  of peptide  trans- 
porter,  LMP  genes,  and possible additional  factors that  are 
essential for class I  transport,  is caused by viral transforma- 
tion  and  may  provide  escape  mechanisms  from  immune 
surveillance.  Moreover,  only  certain  oncogenic  viruses 
seem to have the capacity to cause such suppression. Trans- 
formed  cells  that  do  not  express  peptide  transporter  and 
LMP genes and do not transport class  I  molecules present- 
ing  an  immunogenic  tumor-associated  peptide,  may  un- 
dergo selection in vivo and develop into nonimmunogenic 
tumors  with  oncogenic  potential.  Hence,  this  system pro- 
vides a novel model for evaluating the roles of multiple fac- 
tors  in  the class I  biosynthetic  pathway during  tumor pro- 
gression. 
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